|
AU3335301A
|
|
Localization of therapeutic agents
|
|
AU8318698A
|
|
Localization of therapeutic agents
|
|
US5567588A
|
|
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
US5587468A
|
|
High affinity nucleic acid ligands to HIV integrase
|
|
AU2470295A
|
|
High-affinity ligands of insulin receptor antibodies, tachykinin substance p, hiv integrase and hiv-1 reverse transcriptase
|
|
US5648214A
|
|
High-affinity oligonucleotide ligands to the tachykinin substance P
|
|
US5503978A
|
|
Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
|
|
AU5961994A
|
|
Localization of therapeutic agents
|
|
US5667969A
|
|
Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
|
|
AU5442194A
|
|
Method for selecting nucleic acids on the basis of structure
|
|
US5596434A
|
|
Self-assembled monolayers for liquid crystal alignment
|
|
US5270163A
|
|
Methods for identifying nucleic acid ligands
|
|
WO9401536A1
|
|
Cancer immunotherapy with antibodies to cancer procoagulant
|
|
US5543078A
|
|
Ferroelectric liquid crystals for nonlinear optics applications
|
|
WO9303172A1
|
|
Systematic polypeptide evolution by reverse translation
|
|
US5223486A
|
|
Inhibition of cancer procoagulant
|
|
AU8206191A
|
|
Nucleic acid ligands
|
|
US5168381A
|
|
Smectic liquid crystal devices using SSFLC and electroclinic effect based cells
|
|
US5180520A
|
|
Ferroelectric liquid crystal compositions containing halogenated cores and chiral halogenated cores and chiral haloalkoxy tail units
|
|
US5167855A
|
|
Ferroelectric liquid crystal compositions chiral haloalkoxy tail units
|
